Loading...
Clinical Response and Quality of Life in Patients with Severe Atopic Dermatitis Treated with Dupilumab: A Single-Center Real-Life Experience
Dupilumab is an anti-interleukin-4 receptor monoclonal antibody that was recently approved for the treatment of atopic dermatitis (AD). In this single-center retrospective study, clinical baseline data of 117 severe AD patients treated with dupilumab were collected. At baseline and at weeks 4 and 16...
Na minha lista:
| Udgivet i: | J Clin Med |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
MDPI
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7141229/ https://ncbi.nlm.nih.gov/pubmed/32183179 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9030791 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|